Pharming Group N.V annual return on assets (roa)
2020
2021
2022
2023
2024
2025
Pharming Group N.V Return on Assets (ROA) Growth & History (PHAR)
Pharming Group N.V's return on assets (roa) was 0.56% for fiscal 2025.
View full Pharming Group N.V company overviewPharming Group N.V annual return on assets (roa) history
| Fiscal year | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 0.56% | +3.31 pp |
| 2024 | 2024-12-31 | −2.74% | −0.37 pp |
| 2023 | 2023-12-31 | −2.37% | −5.70 pp |
| 2022 | 2022-12-31 | 3.32% | −0.60 pp |
| 2021 | 2021-12-31 | 3.92% | −7.27 pp |
| 2020 | 2020-12-31 | 11.19% | — |
Pharming Group N.V quarterly return on assets (roa)
Q1.26
Q2.26
| Fiscal quarter | Period ended | Return on assets (ROA) | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | 2.03% | — |
| Q1 2026 | 2026-03-31 | 2.77% | — |
Pharming Group N.V return on assets (roa) trends
Over the last five fiscal years, Pharming Group N.V's return on assets (roa) decreased from 11.19% to 0.56%, a change of −10.63 percentage points. The latest reported quarter, Q2 2026, shows 2.03%.
About the metric
What return on assets means
Return on assets measures profit relative to the assets used to generate it. It can help compare operating efficiency over time, although normal ROA differs substantially between asset-light and asset-intensive industries.
Calculation and source
How return on assets is calculated
TickerStat calculates annual ROA as reported net income divided by average total assets. Quarterly observations use trailing-12-month net income and average assets over the corresponding one-year period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharming Group N.V source filings ↗Community posts
Pharming expands Joenja approval to younger children with APDS
Pharming ($PHAR) secured FDA approval to use Joenja in children aged four to 11 with activated PI3K delta syndrome who weigh at least 27 kilograms. The expansion adds younger patients to the medicine’s existing indication for older patients ...